Cargando…

Exploring the failing right ventricle in pulmonary hypertension by cardiac magnetic resonance: An in vivo study utilizing Macitentan

Cardiac magnetic resonance (CMR) imaging is used to assess the right ventricle (RV) of pulmonary hypertensive (PH) patients and more recently to track changes in response to therapy. We wished to investigate if repeat CMRs could be used to assess ventricular changes in the Sugen 5416 hypoxic (Su/Hx)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murphy, Gerard, Jayasekera, Geeshath, Mullin, James, Gallagher, Lindsay, Welsh, David J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438403/ https://www.ncbi.nlm.nih.gov/pubmed/36092794 http://dx.doi.org/10.1002/pul2.12124

Ejemplares similares

Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats
por: Mamazhakypov, Argen, et al.
Publicado: (2020)

Right Ventricular free wall myocardial tissue characterisation by systolic Cardiac Magnetic Resonance T1 mapping in pulmonary hypertension
por: Jayasekera, Geeshath, et al.
Publicado: (2016)

Pulmonary hypertension and severe right heart failure following lumbar spinal surgery
por: Jayasekera, Geeshath, et al.
Publicado: (2019)

Understanding longitudinal biventricular structural and functional changes in a pulmonary hypertension Sugen–hypoxia rat model by cardiac magnetic resonance imaging
por: Jayasekera, Geeshath, et al.
Publicado: (2020)

Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
por: Monaco, Thomas J, et al.
Publicado: (2016)

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension
por: Nosrati, Marzieh, et al.
Publicado: (2020)

Macitentan for the treatment of pulmonary arterial hypertension
por: Kholdani, Cyrus A, et al.
Publicado: (2014)

Non-invasive imaging of global and regional cardiac function in pulmonary hypertension
por: Crowe, Tim, et al.
Publicado: (2017)

Myofiber organization in the failing systemic right ventricle
por: Campanale, Cosimo M., et al.
Publicado: (2020)

Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
por: Said, Karim
Publicado: (2014)

Macitentan in the treatment of pulmonary hypertension in Gaucher’s disease
por: Taylan, Gökay, et al.
Publicado: (2020)

Gently handling the acutely failing right ventricle … at last!
por: Lorusso, Roberto, et al.
Publicado: (2021)

Macitentan: An important addition to the treatment of pulmonary arterial hypertension
por: Khadka, Anjan, et al.
Publicado: (2015)

Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension
por: Iglarz, Marc, et al.
Publicado: (2015)

Magnetic resonance imaging of the right ventricle in pediatric pulmonary arterial hypertension
por: Blalock, Shannon, et al.
Publicado: (2013)

Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension
por: Kuc, Rhoda E., et al.
Publicado: (2014)

Benefits from the Early Initiation of Macitentan for Pulmonary Arterial Hypertension
por: Jung, Hae Ok
Publicado: (2018)

Safety and tolerability of macitentan in the management of pulmonary arterial hypertension: an update
por: Wong, Alexandra K, et al.
Publicado: (2019)

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Efficacy and safety of macitentan for pulmonary hypertension: A meta‐analysis
por: Du, Dan, et al.
Publicado: (2023)

An integrated proteomic and transcriptomic signature of the failing right ventricle in monocrotaline induced pulmonary arterial hypertension in male rats
por: Hindmarch, Charles Colin Thomas, et al.
Publicado: (2022)

The right ventricle in pulmonary arterial hypertension
por: Naeije, Robert, et al.
Publicado: (2014)

Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-series
por: Mathijssen, H., et al.
Publicado: (2020)

Macitentan treatment retards the progression of established pulmonary arterial hypertension in an animal model()
por: Temple, I.P., et al.
Publicado: (2014)

Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial
por: Jansa, Pavel, et al.
Publicado: (2017)

Triple oral combination therapy with macitentan, riociguat, and selexipag for pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2021)

Effects of bergapten on the pharmacokinetics of macitentan in rats both in vitro and in vivo
por: Xu, Jia, et al.
Publicado: (2023)

Assessment of right ventricle in pulmonary arterial hypertension with three-dimensional echocardiography and cardiovascular magnetic resonance
por: Lattanzio, Mariangela, et al.
Publicado: (2021)

Energy Metabolism in the Failing Right Ventricle: Limitations of Oxygen Delivery and the Creatine Kinase System
por: Fowler, Ewan D., et al.
Publicado: (2019)

Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
por: Tynan, Timothy, et al.
Publicado: (2019)

Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension
por: Sulica, Roxana, et al.
Publicado: (2019)

The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up
por: Jariwala, Pankaj, et al.
Publicado: (2022)

Macitentan treatment of portopulmonary hypertension with hepatopulmonary syndrome: a case report and literature review
por: Li, Niuniu, et al.
Publicado: (2023)

Evaluation of right ventricle with echocardiography: Utility of combined techniques
por: Yalcinkaya, Emre, et al.
Publicado: (2013)

Right Ventricle Remodeling in Chronic Thromboembolic Pulmonary Hypertension
por: Liu, Jixiang, et al.
Publicado: (2022)

Hemodynamic and Histopathologic Benefits of Early Treatment with Macitentan in a Rat Model of Pulmonary Arterial Hypertension
por: Kim, Kyung-Hee, et al.
Publicado: (2018)

Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
por: Belge, Catharina, et al.
Publicado: (2019)

Prospective clinical assessment of patients with pulmonary arterial hypertension switched from bosentan to macitentan (POTENT)
por: Aldalaan, Abdullah M., et al.
Publicado: (2022)

Assessment of the right ventricle with cardiovascular magnetic resonance at 7 Tesla
por: von Knobelsdorff-Brenkenhoff, Florian, et al.
Publicado: (2013)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gcibq0b7f7qc118309978lq0ae